PETR3:BMFBOVESPAPetroleo Brasileiro SA Analysis
Data as of 2026-07-08 - not real-time
R$42.96
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Petrobras (PETR3) trades at BRL 42.96, well below its DCF-derived fair value of BRL 61.14, implying roughly 31% upside. The stock benefits from a very low PE ratio of 5.28 versus the industry average of 20.67 and a robust dividend yield of 9.07% with a modest payout ratio of 31%, indicating dividend sustainability. Technicals show the price just above the 20‑day SMA (43.34) and below the 50‑day SMA (47.24), with a bullish MACD histogram and RSI at 41, suggesting a neutral to slightly positive short‑term bias. Volume trends are decreasing, but the stock sits on a solid support at BRL 41.32 and faces resistance near BRL 47.57. Fundamentals remain strong: operating margin of 31.9%, ROE of 25.6%, and free cash flow of BRL 82.9 bn support the valuation case. Recent material news on the approved Final Investment Decision for the RPBC Biorefining project adds a growth catalyst in the low‑carbon segment, enhancing the long‑term narrative.
Given the blend of deep discount, attractive yield, and strategic initiatives, PETR3 appears positioned for both income‑focused and capital‑appreciation investors. The negative beta (‑0.45) provides a hedge against market moves, while sector‑specific oil price volatility and Brazilian regulatory dynamics keep risk considerations in view. Overall, the stock presents a compelling undervalued, value‑oriented opportunity with upside potential and dividend resilience.
Given the blend of deep discount, attractive yield, and strategic initiatives, PETR3 appears positioned for both income‑focused and capital‑appreciation investors. The negative beta (‑0.45) provides a hedge against market moves, while sector‑specific oil price volatility and Brazilian regulatory dynamics keep risk considerations in view. Overall, the stock presents a compelling undervalued, value‑oriented opportunity with upside potential and dividend resilience.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price near support level (BRL 41.32) with bullish MACD histogram
- High dividend yield offering immediate income
- Undervalued relative to DCF fair value
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Upside potential of ~31% to fair value
- Strong cash generation and low payout ratio
- Analyst consensus strong‑buy with median target BRL 60
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic biorefining project expanding low‑carbon portfolio
- Sustained dividend policy supported by robust free cash flow
- Long‑term undervaluation despite high debt, supported by diversified operations
Key Metrics & Analysis
Financial Health
Revenue Growth0.40%
Profit Margin21.60%
P/E Ratio5.3
ROE25.60%
ROA8.23%
Debt/Equity83.27
P/B Ratio1.2
Op. Cash FlowR$195.0B
Free Cash FlowR$82.9B
Industry P/E20.7
Technical Analysis
TrendNeutral
RSI41.2
SupportR$41.32
ResistanceR$47.57
MA 20R$43.34
MA 50R$47.24
MA 200R$40.94
MACDBullish
VolumeDecreasing
Fear & Greed Index90.27
Valuation
Fair ValueR$61.14
Target PriceR$56.43
Upside/Downside31.35%
GradeUndervalued
TypeValue
Dividend Yield9.07%
Risk Assessment
Beta-0.45
Volatility24.06%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.